FTO Enzyme Presents Potential Cancer Therapy Target
A new medical review highlights how inhibiting the FTO enzyme could influence tumor growth in gastrointestinal cancers.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Do you trust that emerging cancer research leads to meaningful improvements in patient treatment?
A recently published review identifies the FTO enzyme as a key target for treating gastrointestinal cancers due to its role in regulating RNA. Researchers note that small-molecule inhibitors are showing promise in experimental settings.
Why it matters
Because FTO can function as both an oncogene and a tumor suppressor, understanding its specific molecular context is vital for developing effective therapies. This dual nature requires nuanced strategies to avoid unintended effects in cancer treatment.
The review in Genes & Diseases Volume 13, Issue 6 details how FTO functions as an RNA demethylase that removes N6-methyladenosine modifications. Experimental studies have identified several small-molecule inhibitors, including Rhein, FB23-2, CS1/CS2, Dac51, and 18097.
The details
The enzyme FTO significantly influences RNA stability, translation, and cellular movement, impacting tumor growth, metastasis, and treatment resistance. Post-translational modifications like acetylation and ubiquitination regulate its activity, suggesting that targeting the enzyme could potentially complement future immunotherapy approaches.
Timeline
The review was published in Genes & Diseases Volume 13 during 2026.
The Big Picture
This discovery shifts the scientific trajectory by focusing on RNA demethylase activity as a regulatory checkpoint in oncology. It moves beyond traditional DNA-centric models to explore how the epitranscriptome influences the progression and treatment resistance of gastrointestinal tumors.
While these findings are currently confined to experimental and laboratory settings, they suggest a future pathway for more personalized cancer treatments. Patients should continue to follow standard medical guidance as these compounds are not yet available for clinical use.
The takeaway
The dual role of FTO as both an oncogene and tumor suppressor highlights the importance of context-specific medicine in future drug development. Researchers suggest that future therapies will likely require precise targeting strategies to safely manage tumor growth.
Further reading
For more information on the latest advancements in this field, visit our Cancer section.
Live Poll
Do you trust that emerging cancer research leads to meaningful improvements in patient treatment?
